Evidence map›Paper›PMID 36531558›Full record

Trial reportInternational journal of clinical practice2022

Effects of Isoflavone Supplementation on the Response to Medroxyprogesterone in Premenopausal Women with Nonatypical Endometrial Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled Trial.

Zahra Vahedpour, Homa Boroumand, Shirin Tabatabaee Anaraki, Zohre Tabasi, Hossein Motedayyen, Hossein Akbari, Fariba Raygan, Vahidreza Ostadmohammadi

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of clinical practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Zahra VahedpourDepartment of Gynecology and Obstetrics, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Homa BoroumandInfectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.ORCID https://orcid.org/0000-0002-2323-0082
Shirin Tabatabaee AnarakiDepartment of Gynecology and Obstetrics, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.ORCID https://orcid.org/0000-0002-7230-3591
Zohre TabasiDepartment of Gynecology and Obstetrics, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Hossein MotedayyenAutoimmune Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Hossein AkbariDepartment of Biostatistics and Epidemiology, Faculty of Public Health, Kashan University of Medical Sciences, Kashan, Iran.
Fariba RayganDepartment of Cardiology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.ORCID https://orcid.org/0000-0003-3789-5584
Vahidreza OstadmohammadiInfectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.ORCID https://orcid.org/0000-0002-4633-5397
Kashan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The purpose of this study was to evaluate the impact of isoflavone supplementation compared with placebo on endometrial histology and serum estradiol levels in premenopausal women with nonatypical endometrial hyperplasia. Materials and Methods: The present double-blindplacebo-controlled clinical trial was conducted on 100 women with nonatypical endometrial hyperplasia in the age range of 30 to 45 years. Participants were randomly assigned to receive 50 mg of isoflavone ( Results: After three months, 88.4% of isoflavone-administered subjects had a significant histological improvement compared to 68.9% subjects in the placebo group ( Conclusion: The findings of the present study demonstrated that the coadministration of 50 mg of isoflavones and medroxyprogesterone acetate increases the treatment efficacy in women with nonatypical endometrial hyperplasia.

Indexed as

Drug-Related Side Effects and Adverse ReactionsEndometrial HyperplasiaIsoflavonesAdultDietary SupplementsDouble-Blind MethodEstradiolFemaleHumansIranMedroxyprogesteroneMiddle AgedEstradiolIsoflavonesMedroxyprogesterone

Identifiers

PMID36531558
PMCPMC9715344
OpenAlexW4309907084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.